<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Respiratory</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>United’s Tyvaso nails endpoints in second phase III IPF trial</title>
      <description>
        <![CDATA[United Therapeutics Corp. is eyeing a possible priority review in its anticipated supplemental NDA for Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) after the second phase III trial hit its endpoints, even besting the impressive findings from the first phase III study reported last year, and positioning United for a substantial commercial launch in 2027.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729947</guid>
      <pubDate>Mon, 30 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729947-uniteds-tyvaso-nails-endpoints-in-second-phase-iii-ipf-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Tyvaso-nebulizer.webp?t=1756849279" type="image/jpeg" medium="image" fileSize="703312">
        <media:title type="plain">Tyvaso nebulizer</media:title>
        <media:description type="plain">Tyvaso inhalation system. Credit: United Therapeutics Corp. </media:description>
      </media:content>
    </item>
    <item>
      <title>Pinnacle raises an $89M series B for its oral peptide programs</title>
      <description>
        <![CDATA[Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730034</guid>
      <pubDate>Fri, 27 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730034-pinnacle-raises-an-89m-series-b-for-its-oral-peptide-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/finance-dollar-growth.webp?t=1638226495" type="image/png" medium="image" fileSize="416016">
        <media:title type="plain">Hand holding dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Pinnacle raises an $89M series B for its oral peptide programs</title>
      <description>
        <![CDATA[Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729903</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729903-pinnacle-raises-an-89m-series-b-for-its-oral-peptide-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/finance-dollar-growth.webp?t=1638226495" type="image/png" medium="image" fileSize="416016">
        <media:title type="plain">Hand holding dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Multibody TEV‘325 achieves preclinical milestone</title>
      <description>
        <![CDATA[Biolojic Design Ltd. has earned an additional milestone payment from its collaboration partner, Teva Pharmaceutical Industries Ltd., for TEV‘325 (TEV-56308, formerly BD-9), a multibody targeting IL-13 and thymic stromal lymphopoietin (TSLP) for autoimmune disease]]>
      </description>
      <guid>http://www.bioworld.com/articles/729930</guid>
      <pubDate>Thu, 26 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729930-multibody-tev325-achieves-preclinical-milestone</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/collaboration-research-milestones-illustration.webp?t=1735313933" type="image/jpeg" medium="image" fileSize="78720">
        <media:title type="plain">Illustration of a road with three destination markers</media:title>
      </media:content>
    </item>
    <item>
      <title>circPTK2 unveiled as a driver of pulmonary fibrosis</title>
      <description>
        <![CDATA[Pulmonary fibrosis (PF) is a fatal lung disease characterized by excessive deposition of extracellular matrix proteins in the lung interstitium due to excessive fibroblast activation, which leads to tissue scarring and potential respiratory failure. Chinese researchers have published results of their investigations into circular RNAs and the pathogenesis of PF.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729725</guid>
      <pubDate>Thu, 19 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729725-circptk2-unveiled-as-a-driver-of-pulmonary-fibrosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Respiratory-lungs-inflammation.webp?t=1698075497" type="image/jpeg" medium="image" fileSize="261810">
        <media:title type="plain">AI generated illustration of lungs in the human body</media:title>
      </media:content>
    </item>
    <item>
      <title>CSPC Zhongqi Pharmaceutical Technology synthesizes PDE4B2 inhibitors</title>
      <description>
        <![CDATA[CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has disclosed crystalline forms of phosphodiesterase PDE4B2 inhibitors. They are reported to be useful for the treatment of chronic obstructive pulmonary disease, interstitial lung diseases and asthma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729702</guid>
      <pubDate>Wed, 18 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729702-cspc-zhongqi-pharmaceutical-technology-synthesizes-pde4b2-inhibitors</link>
    </item>
    <item>
      <title>CF Pharmtech’s ICF-001 cleared for clinic in China</title>
      <description>
        <![CDATA[CF Pharmtech Inc. has announced IND approval by China’s National Medical Products Administration (NMPA) for ICF-001, a long-acting inhalation powder candidate for the treatment of pulmonary hypertension and related severe pulmonary diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729648</guid>
      <pubDate>Mon, 16 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729648-cf-pharmtechs-icf-001-cleared-for-clinic-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Respiratory-Disorders.webp?t=1589292629" type="image/png" medium="image" fileSize="574575">
        <media:title type="plain">Internal organs: lungs, heart, stomach, diaphragm</media:title>
      </media:content>
    </item>
    <item>
      <title>Enanta Pharmaceuticals presents data for KIT inhibitor EDP-978</title>
      <description>
        <![CDATA[The activation of mast cells in the lungs and skin is involved in diseases such as asthma and chronic spontaneous urticaria, where the KIT receptor tyrosine kinase is a key regulator of mast cell function.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729627</guid>
      <pubDate>Fri, 13 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729627-enanta-pharmaceuticals-presents-data-for-kit-inhibitor-edp-978</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Immune/mast-cell-histamine-illustration.webp?t=1755723604" type="image/jpeg" medium="image" fileSize="116465">
        <media:title type="plain">Illustration of a mast cell releasing histamines</media:title>
      </media:content>
    </item>
    <item>
      <title>Baseimmune expands into fibrosis</title>
      <description>
        <![CDATA[Baseimmune Ltd. has announced its strategic expansion into fibrosis, with a new fibrosis-focused pipeline led by a program for idiopathic pulmonary fibrosis (IPF). ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729607</guid>
      <pubDate>Thu, 12 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729607-baseimmune-expands-into-fibrosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Respiratory-lung-alveoli.webp?t=1745266926" type="image/jpeg" medium="image" fileSize="332757">
        <media:title type="plain">Illustration of alveoli and lungs</media:title>
      </media:content>
    </item>
    <item>
      <title>Korean ARPA-H to invest ₩162B in nine projects in 2026</title>
      <description>
        <![CDATA[The K-health MIRAE Initiative, also known as Korean ARPA-H, announced plans to allocate about ₩162 billion (US$110 million) in nine new projects over the next five years, with a focus on strengthening national health security.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729582</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729582-korean-arpa-h-to-invest-162b-in-nine-projects-in-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Korea-ARPA-H-roundtable-3-6.webp?t=1772832533" type="image/jpeg" medium="image" fileSize="642632">
        <media:title type="plain">Korea ARPA-H roundtable</media:title>
        <media:description type="plain">K-health MIRAE Initiative Director General Sun Kyung, center, and project managers at a roundtable meeting in Seoul, South Korea on March 5.</media:description>
      </media:content>
    </item>
    <item>
      <title>Korean ARPA-H to invest ₩162B in nine projects in 2026</title>
      <description>
        <![CDATA[The K-health MIRAE Initiative, also known as Korean ARPA-H, announced plans to allocate about ₩162 billion (US$110 million) in nine new projects over the next five years, with a focus on strengthening national health security.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729359</guid>
      <pubDate>Fri, 06 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729359-korean-arpa-h-to-invest-162b-in-nine-projects-in-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Korea-ARPA-H-roundtable-3-6.webp?t=1772832533" type="image/jpeg" medium="image" fileSize="642632">
        <media:title type="plain">Korea ARPA-H roundtable</media:title>
        <media:description type="plain">K-health MIRAE Initiative Director General Sun Kyung, center, and project managers at a roundtable meeting in Seoul, South Korea on March 5.</media:description>
      </media:content>
    </item>
    <item>
      <title>Potent and selective inhaled PDE4 inhibitor for COPD therapy</title>
      <description>
        <![CDATA[Researchers at Shenyang Pharmaceutical University reported the discovery and preclinical evaluation of a PDE4 inhibitor as a potential treatment for chronic obstructive pulmonary disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729390</guid>
      <pubDate>Fri, 06 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729390-potent-and-selective-inhaled-pde4-inhibitor-for-copd-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Lungs-and-bronchi.webp?t=1663277688" type="image/png" medium="image" fileSize="359978">
        <media:title type="plain">Lungs and bronchi</media:title>
      </media:content>
    </item>
    <item>
      <title>Moderna to pay up to $2.25B to settle COVID-19 patents case</title>
      <description>
        <![CDATA[In what it says could be the largest disclosed patent settlement in the pharmaceutical industry, Roivant Sciences Ltd. has reached a potential $2.25 billion settlement with Moderna Inc. over the use of its lipid nanoparticle delivery technology in the Spikevax COVID-19 vaccine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729387</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729387-moderna-to-pay-up-to-225b-to-settle-covid-19-patents-case</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Moderna-Spikevax-9-2.webp?t=1772645697" type="image/jpeg" medium="image" fileSize="152907">
        <media:title type="plain">Spikevax vial and product packaging</media:title>
        <media:description type="plain">Credit: Moderna Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Antiverse announces series A financing, tie-up with CF Foundation</title>
      <description>
        <![CDATA[Antiverse Ltd. has announced the close of a $9.3 million series A financing. The funding will support expansion of the company’s proprietary AI antibody design platform, accelerate development of its internal therapeutic pipeline, and advance lead antibody programs toward in vivo efficacy studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729324</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729324-antiverse-announces-series-a-financing-tie-up-with-cf-foundation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Antibodies-research-discovery-immune.webp?t=1772641847" type="image/jpeg" medium="image" fileSize="240482">
        <media:title type="plain">Illustration of magnifying glass and antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Returning to pulmonary hypertension, GSK buys 35Pharma </title>
      <description>
        <![CDATA[GSK plc is paying $950 million cash to acquire 100% of 35Pharma Inc.’s equity and pipeline, including phase II-ready candidate HS-235 for pulmonary hypertension. The acquisition agreement comes a day after GSK added two small interfering RNA assets from Nanjing, China-based Frontier Biotechnologies Inc. through a license deal reaching up to $1 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729368</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729368-returning-to-pulmonary-hypertension-gsk-buys-35pharma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Lungs-heart-anatomy.webp?t=1772042014" type="image/jpeg" medium="image" fileSize="519932">
        <media:title type="plain">Lungs, heart anatomy </media:title>
      </media:content>
    </item>
    <item>
      <title>Systimmune’s iza-bren hits phase III breast cancer goals in China</title>
      <description>
        <![CDATA[In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729321</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729321-systimmunes-iza-bren-hits-phase-iii-breast-cancer-goals-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/breast-cancer-wireframe.webp?t=1706887459" type="image/jpeg" medium="image" fileSize="349651">
        <media:title type="plain">Cancer tumor in breast illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Systimmune’s iza-bren hits phase III breast cancer goals in China</title>
      <description>
        <![CDATA[In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729258</guid>
      <pubDate>Fri, 27 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729258-systimmunes-iza-bren-hits-phase-iii-breast-cancer-goals-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/breast-cancer-wireframe.webp?t=1706887459" type="image/jpeg" medium="image" fileSize="349651">
        <media:title type="plain">Cancer tumor in breast illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>TSLP still plays well, Generates $400M IPO </title>
      <description>
        <![CDATA[Generate Biomedicines Inc. proved that enthusiasm hasn’t waned for TSLP as a target by pricing an IPO selling 25 million shares at $16 each for proceeds of $400 million. Generate’s lead compound is phase III-stage TSLP-targeting antibody GB-0895 and the company’s assigned Nasdaq ticker is GENB. The offering is expected to close on March 2.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729255</guid>
      <pubDate>Fri, 27 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729255-tslp-still-plays-well-generates-400m-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/IPO-money.webp?t=1589580854" type="image/png" medium="image" fileSize="658149">
        <media:title type="plain">IPO money</media:title>
      </media:content>
    </item>
    <item>
      <title>Cathepsin L inhibitors disclosed in Biofront Therapeutics patent</title>
      <description>
        <![CDATA[Biofront Therapeutics (Beijing) Co. Ltd. has prepared and tested cathepsin L (CTSL) inhibitors potentially useful for the treatment of acute respiratory distress syndrome (ARDS), cancer, diabetes, liver injury, viral infections and bone, inflammatory and renal disorders, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729065</guid>
      <pubDate>Thu, 26 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729065-cathepsin-l-inhibitors-disclosed-in-biofront-therapeutics-patent</link>
    </item>
    <item>
      <title>CF Pharmtech’s ICF-004 cleared for clinical trials in China</title>
      <description>
        <![CDATA[CF Pharmtech Inc. has announced approval from China’s National Medical Products Administration (NMPA) of an IND application filed by subsidiary Changfeng Suyue Pharmaceutical (Guangzhou) Co. Ltd. for ICF-004.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729056</guid>
      <pubDate>Thu, 26 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729056-cf-pharmtechs-icf-004-cleared-for-clinical-trials-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Lungs-with-alveoli.webp?t=1758058023" type="image/jpeg" medium="image" fileSize="313044">
        <media:title type="plain">Lungs with alveoli</media:title>
      </media:content>
    </item>
    <item>
      <title>United unveils newly partnered soft mist inhaler; Mannkind sinks</title>
      <description>
        <![CDATA[United Therapeutics Corp.’s founder, chairman and CEO Martine Rothblatt disclosed during the company’s fourth-quarter earnings call Feb. 25 the “unsheathing of a category killer product” known as Tresmi, a drug-device formulation of treprostinil delivered via a soft mist inhaler.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729204</guid>
      <pubDate>Wed, 25 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729204-united-unveils-newly-partnered-soft-mist-inhaler-mannkind-sinks</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Respiratory-lungs-wireframe.webp?t=1588285653" type="image/png" medium="image" fileSize="377769">
        <media:title type="plain">Lungs wireframe illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Returning to pulmonary hypertension, GSK buys 35Pharma </title>
      <description>
        <![CDATA[GSK plc is paying $950 million cash to acquire 100% of 35Pharma Inc.’s equity and pipeline, including phase II-ready candidate HS-235 for pulmonary hypertension. The acquisition agreement comes a day after GSK added two small interfering RNA assets from Nanjing, China-based Frontier Biotechnologies Inc. through a license deal reaching up to $1 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729199</guid>
      <pubDate>Wed, 25 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729199-returning-to-pulmonary-hypertension-gsk-buys-35pharma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Lungs-heart-anatomy.webp?t=1772042014" type="image/jpeg" medium="image" fileSize="519932">
        <media:title type="plain">Lungs, heart anatomy </media:title>
      </media:content>
    </item>
    <item>
      <title>ROMO1 behind COPD pathogenesis, study finds</title>
      <description>
        <![CDATA[Current therapies for chronic obstructive pulmonary disease (COPD) alleviate symptoms, but do not deal with disease progression. Respiratory mucus is primarily made up of mucins, of which mucin 5AC (MUC5AC) is the most predominant in COPD. It was hypothesized that mitochondria may control the expression of MUC5AC in COPD airway epithelium by modulating intracellular reactive oxygen species (ROS) levels.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728903</guid>
      <pubDate>Tue, 17 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728903-romo1-behind-copd-pathogenesis-study-finds</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/COPD-chronic-obstructive-pulmonary-disease-research.webp?t=1771344341" type="image/jpeg" medium="image" fileSize="274563">
        <media:title type="plain">Illustration of lungs with microscope</media:title>
      </media:content>
    </item>
    <item>
      <title>Upstream’s verekitug boat floats in asthma phase II</title>
      <description>
        <![CDATA[Upstream Bio Inc.’s favorable top-line results from the phase II Valiant trial testing verekitug in adults with severe asthma were not enough to charm Wall Street, and shares of the firm (NASDAQ:UPB) closed Feb. 11 at $14.69, down $13.12, or 47%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728727</guid>
      <pubDate>Wed, 11 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728727-upstreams-verekitug-boat-floats-in-asthma-phase-ii</link>
    </item>
    <item>
      <title>4dmedical raises $105M to bolster U.S. CT:VQ lead</title>
      <description>
        <![CDATA[Australian respiratory imaging technology company 4dmedical Ltd. raised AU$150 million (US$105 million) in an institutional placement to accelerate U.S. adoption of its CT:VQ lung imaging software to bolster the company’s lead in software-based lung imaging.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728274</guid>
      <pubDate>Thu, 29 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728274-4dmedical-raises-105m-to-bolster-us-ct-vq-lead</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2026/4DMedical_Respiratory_Imaging-29jan26.webp?t=1769717388" type="image/jpeg" medium="image" fileSize="80582">
        <media:title type="plain">4DMedical Respiratory Imaging</media:title>
        <media:description type="plain">Melbourne-headquartered 4dmedical is advancing its respiratory imaging technology and expanding the U.S. rollout of its FDA-cleared CT:VQ software that measures ventilation and perfusion in the lungs. Credit: 4dmedical</media:description>
      </media:content>
    </item>
    <item>
      <title>Study digs into links between age, sex, hormones and asthma</title>
      <description>
        <![CDATA[The prevalence of asthma differs between men and women, and furthermore, the difference changes over the lifespan. “Asthma is more common in boys than girls, but more common in women than men,” Clare Lloyd told <em>BioWorld</em>. Females are particularly susceptible to asthma during developmental periods of hormonal changes, also known as puberty, pregnancy and menopause.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728498</guid>
      <pubDate>Wed, 28 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728498-study-digs-into-links-between-age-sex-hormones-and-asthma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Blue-lungs.webp?t=1694726337" type="image/jpeg" medium="image" fileSize="130454">
        <media:title type="plain">Lungs</media:title>
      </media:content>
    </item>
    <item>
      <title>β3-Adrenoceptor agonism plays protective role in bronchopulmonary dysplasia</title>
      <description>
        <![CDATA[Bronchopulmonary dysplasia (BPD) is a chronic disease of the lungs that mainly affects premature newborns, especially those who receive mechanical ventilation, which can contribute to altering normal lung development. There are few treatment options with limited efficacy to improve the prognosis of BPD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728395</guid>
      <pubDate>Wed, 28 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728395-3-adrenoceptor-agonism-plays-protective-role-in-bronchopulmonary-dysplasia</link>
    </item>
    <item>
      <title>Study digs into links between age, sex, hormones and asthma</title>
      <description>
        <![CDATA[The prevalence of asthma differs between men and women, and furthermore, the difference changes over the lifespan. “Asthma is more common in boys than girls, but more common in women than men,” Clare Lloyd told <em>BioWorld</em>. Females are particularly susceptible to asthma during developmental periods of hormonal changes, also known as puberty, pregnancy and menopause.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728354</guid>
      <pubDate>Mon, 26 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728354-study-digs-into-links-between-age-sex-hormones-and-asthma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Blue-lungs.webp?t=1694726337" type="image/jpeg" medium="image" fileSize="130454">
        <media:title type="plain">Lungs</media:title>
      </media:content>
    </item>
    <item>
      <title>MicroRNAs in circulating extracellular vesicles as IPF biomarkers</title>
      <description>
        <![CDATA[MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular processes and diseases. miRNAs can be encapsulated in extracellular vesicles (EVs), which are released by most cell types to modulate gene expression in recipient cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728301</guid>
      <pubDate>Fri, 23 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728301-micrornas-in-circulating-extracellular-vesicles-as-ipf-biomarkers</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Health-research-biomarkers.webp?t=1735574503" type="image/jpeg" medium="image" fileSize="1066689">
        <media:title type="plain">Art concept for medical research</media:title>
      </media:content>
    </item>
    <item>
      <title>Beijing Tide Pharmaceutical divulges new cathepsin C inhibitors</title>
      <description>
        <![CDATA[Beijing Tide Pharmaceutical Co. Ltd. has patented new cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of bronchiectasis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728218</guid>
      <pubDate>Fri, 23 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728218-beijing-tide-pharmaceutical-divulges-new-cathepsin-c-inhibitors</link>
    </item>
  </channel>
</rss>
